Intelligence Feed event · Credit · 2026-10-06

    Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share

    Question

    Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share

    Direct answer

    Spyre Therapeutics has priced an underwritten public offering of common stock to secure approximately $350 million in gross financing at a price of $85.00 per share. The transaction provides substantial capital backing for its late-stage clinical programs. The raised capital will be allocated toward Phase 3 operational readiness and advancing development programs in inflammatory and immunological disorders across gastroenterology, rheumatology, and dermatology indications.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-06
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share”, revision 1, evidence through 2026-10-06. https://marketontology.com/market-events/2026-10-06/spyre-therapeutics-prices-350-million-public-equity-offering-at-85-per-share-70194a

    CREDIT
    Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share
    Spyre Therapeutics has priced an underwritten public offering of common stock to secure approximately $350 million in gross financing at a price of $85.00 per share. The transaction provides substantial capital backing for its late-stage clinical programs. The raised capital will be allocated toward Phase 3 operational readiness and advancing development programs in inflammatory and immunological disorders across gastroenterology, rheumatology, and dermatology indications.
    SYREXBI
    Impact
    68
    OCT 6
    SIG
    90%
    SYREXBI
    Spyre Therapeutics Prices $350 Million Public Equity Offering at $85 Per Share
    Spyre Therapeutics has priced an underwritten public offering of common stock to secure approximately $350 million in gross financing at a price of $85.00 per share. The transaction provides substantial capital backing for its late-stage clinical programs. The raised capital will be allocated toward Phase 3 operational readiness and advancing development programs in inflammatory and immunological disorders across gastroenterology, rheumatology, and dermatology indications.
    → Primary equity issuance at $85 per share eliminates near-term clinical financing overhang while causing immediate equity dilution.
    Impact
    Spyre Therapeutics has priced an underwritten public offering of common stock to secure approximately $350 million in gross financing at a price of $85.00 per share. The transaction provides substantial capital backing for its late-stage clinical programs. The raised capital will be allocated toward Phase 3 operational readiness and advancing development programs in inflammatory and immunological disorders across gastroenterology, rheumatology, and dermatology indications.
    Affected
    SYREXBI
    Transmission
    Primary equity issuance at $85 per share eliminates near-term clinical financing overhang while causing immediate equity dilution.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    SYREequity dilution balanced by balance sheet de-risking for Phase 3 trialsMixed1-5dPriced $350M public offering of common stock at $85 per share.
    XBIbiotechnology primary equity issuance liquidity absorptionWatch1-4wBroad biotech ECM activity remains active across clinical stage developers.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    XBIWatch154.43 2026-10-02PendingPendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month